Cargando…
Nonsteroidal Antiinflammatory Drugs and Susceptibility to COVID‐19
OBJECTIVE: To identify whether active use of nonsteroidal antiinflammatory drugs (NSAIDs) increases susceptibility to developing suspected or confirmed coronavirus disease 2019 (COVID‐19) compared to the use of other common analgesics. METHODS: We performed a propensity score–matched cohort study wi...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8252419/ https://www.ncbi.nlm.nih.gov/pubmed/33185016 http://dx.doi.org/10.1002/art.41593 |
_version_ | 1783717295782100992 |
---|---|
author | Chandan, Joht Singh Zemedikun, Dawit Tefra Thayakaran, Rasiah Byne, Nathan Dhalla, Samir Acosta‐Mena, Dionisio Gokhale, Krishna M. Thomas, Tom Sainsbury, Christopher Subramanian, Anuradhaa Cooper, Jennifer Anand, Astha Okoth, Kelvin O. Wang, Jingya Adderley, Nicola J. Taverner, Thomas Denniston, Alastair K. Lord, Janet Thomas, G. Neil Buckley, Christopher D. Raza, Karim Bhala, Neeraj Nirantharakumar, Krishnarajah Haroon, Shamil |
author_facet | Chandan, Joht Singh Zemedikun, Dawit Tefra Thayakaran, Rasiah Byne, Nathan Dhalla, Samir Acosta‐Mena, Dionisio Gokhale, Krishna M. Thomas, Tom Sainsbury, Christopher Subramanian, Anuradhaa Cooper, Jennifer Anand, Astha Okoth, Kelvin O. Wang, Jingya Adderley, Nicola J. Taverner, Thomas Denniston, Alastair K. Lord, Janet Thomas, G. Neil Buckley, Christopher D. Raza, Karim Bhala, Neeraj Nirantharakumar, Krishnarajah Haroon, Shamil |
author_sort | Chandan, Joht Singh |
collection | PubMed |
description | OBJECTIVE: To identify whether active use of nonsteroidal antiinflammatory drugs (NSAIDs) increases susceptibility to developing suspected or confirmed coronavirus disease 2019 (COVID‐19) compared to the use of other common analgesics. METHODS: We performed a propensity score–matched cohort study with active comparators, using a large UK primary care data set. The cohort consisted of adult patients age ≥18 years with osteoarthritis (OA) who were followed up from January 30 to July 31, 2020. Patients prescribed an NSAID (excluding topical preparations) were compared to those prescribed either co‐codamol (paracetamol and codeine) or co‐dydramol (paracetamol and dihydrocodeine). A total of 13,202 patients prescribed NSAIDs were identified, compared to 12,457 patients prescribed the comparator drugs. The primary outcome measure was the documentation of suspected or confirmed COVID‐19, and the secondary outcome measure was all‐cause mortality. RESULTS: During follow‐up, the incidence rates of suspected/confirmed COVID‐19 were 15.4 and 19.9 per 1,000 person‐years in the NSAID‐exposed group and comparator group, respectively. Adjusted hazard ratios for suspected or confirmed COVID‐19 among the unmatched and propensity score–matched OA cohorts, using data from clinical consultations in primary care settings, were 0.82 (95% confidence interval [95% CI] 0.62–1.10) and 0.79 (95% CI 0.57–1.11), respectively, and adjusted hazard ratios for the risk of all‐cause mortality were 0.97 (95% CI 0.75–1.27) and 0.85 (95% CI 0.61–1.20), respectively. There was no effect modification by age or sex. CONCLUSION: No increase in the risk of suspected or confirmed COVID‐19 or mortality was observed among patients with OA in a primary care setting who were prescribed NSAIDs as compared to those who received comparator drugs. These results are reassuring and suggest that in the absence of acute illness, NSAIDs can be safely prescribed during the ongoing pandemic. |
format | Online Article Text |
id | pubmed-8252419 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-82524192021-07-07 Nonsteroidal Antiinflammatory Drugs and Susceptibility to COVID‐19 Chandan, Joht Singh Zemedikun, Dawit Tefra Thayakaran, Rasiah Byne, Nathan Dhalla, Samir Acosta‐Mena, Dionisio Gokhale, Krishna M. Thomas, Tom Sainsbury, Christopher Subramanian, Anuradhaa Cooper, Jennifer Anand, Astha Okoth, Kelvin O. Wang, Jingya Adderley, Nicola J. Taverner, Thomas Denniston, Alastair K. Lord, Janet Thomas, G. Neil Buckley, Christopher D. Raza, Karim Bhala, Neeraj Nirantharakumar, Krishnarajah Haroon, Shamil Arthritis Rheumatol Covid‐19 OBJECTIVE: To identify whether active use of nonsteroidal antiinflammatory drugs (NSAIDs) increases susceptibility to developing suspected or confirmed coronavirus disease 2019 (COVID‐19) compared to the use of other common analgesics. METHODS: We performed a propensity score–matched cohort study with active comparators, using a large UK primary care data set. The cohort consisted of adult patients age ≥18 years with osteoarthritis (OA) who were followed up from January 30 to July 31, 2020. Patients prescribed an NSAID (excluding topical preparations) were compared to those prescribed either co‐codamol (paracetamol and codeine) or co‐dydramol (paracetamol and dihydrocodeine). A total of 13,202 patients prescribed NSAIDs were identified, compared to 12,457 patients prescribed the comparator drugs. The primary outcome measure was the documentation of suspected or confirmed COVID‐19, and the secondary outcome measure was all‐cause mortality. RESULTS: During follow‐up, the incidence rates of suspected/confirmed COVID‐19 were 15.4 and 19.9 per 1,000 person‐years in the NSAID‐exposed group and comparator group, respectively. Adjusted hazard ratios for suspected or confirmed COVID‐19 among the unmatched and propensity score–matched OA cohorts, using data from clinical consultations in primary care settings, were 0.82 (95% confidence interval [95% CI] 0.62–1.10) and 0.79 (95% CI 0.57–1.11), respectively, and adjusted hazard ratios for the risk of all‐cause mortality were 0.97 (95% CI 0.75–1.27) and 0.85 (95% CI 0.61–1.20), respectively. There was no effect modification by age or sex. CONCLUSION: No increase in the risk of suspected or confirmed COVID‐19 or mortality was observed among patients with OA in a primary care setting who were prescribed NSAIDs as compared to those who received comparator drugs. These results are reassuring and suggest that in the absence of acute illness, NSAIDs can be safely prescribed during the ongoing pandemic. John Wiley and Sons Inc. 2021-04-29 2021-05 /pmc/articles/PMC8252419/ /pubmed/33185016 http://dx.doi.org/10.1002/art.41593 Text en © 2020 The Authors. Arthritis & Rheumatology published by Wiley Periodicals LLC on behalf of American College of Rheumatology. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Covid‐19 Chandan, Joht Singh Zemedikun, Dawit Tefra Thayakaran, Rasiah Byne, Nathan Dhalla, Samir Acosta‐Mena, Dionisio Gokhale, Krishna M. Thomas, Tom Sainsbury, Christopher Subramanian, Anuradhaa Cooper, Jennifer Anand, Astha Okoth, Kelvin O. Wang, Jingya Adderley, Nicola J. Taverner, Thomas Denniston, Alastair K. Lord, Janet Thomas, G. Neil Buckley, Christopher D. Raza, Karim Bhala, Neeraj Nirantharakumar, Krishnarajah Haroon, Shamil Nonsteroidal Antiinflammatory Drugs and Susceptibility to COVID‐19 |
title | Nonsteroidal Antiinflammatory Drugs and Susceptibility to COVID‐19 |
title_full | Nonsteroidal Antiinflammatory Drugs and Susceptibility to COVID‐19 |
title_fullStr | Nonsteroidal Antiinflammatory Drugs and Susceptibility to COVID‐19 |
title_full_unstemmed | Nonsteroidal Antiinflammatory Drugs and Susceptibility to COVID‐19 |
title_short | Nonsteroidal Antiinflammatory Drugs and Susceptibility to COVID‐19 |
title_sort | nonsteroidal antiinflammatory drugs and susceptibility to covid‐19 |
topic | Covid‐19 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8252419/ https://www.ncbi.nlm.nih.gov/pubmed/33185016 http://dx.doi.org/10.1002/art.41593 |
work_keys_str_mv | AT chandanjohtsingh nonsteroidalantiinflammatorydrugsandsusceptibilitytocovid19 AT zemedikundawittefra nonsteroidalantiinflammatorydrugsandsusceptibilitytocovid19 AT thayakaranrasiah nonsteroidalantiinflammatorydrugsandsusceptibilitytocovid19 AT bynenathan nonsteroidalantiinflammatorydrugsandsusceptibilitytocovid19 AT dhallasamir nonsteroidalantiinflammatorydrugsandsusceptibilitytocovid19 AT acostamenadionisio nonsteroidalantiinflammatorydrugsandsusceptibilitytocovid19 AT gokhalekrishnam nonsteroidalantiinflammatorydrugsandsusceptibilitytocovid19 AT thomastom nonsteroidalantiinflammatorydrugsandsusceptibilitytocovid19 AT sainsburychristopher nonsteroidalantiinflammatorydrugsandsusceptibilitytocovid19 AT subramaniananuradhaa nonsteroidalantiinflammatorydrugsandsusceptibilitytocovid19 AT cooperjennifer nonsteroidalantiinflammatorydrugsandsusceptibilitytocovid19 AT anandastha nonsteroidalantiinflammatorydrugsandsusceptibilitytocovid19 AT okothkelvino nonsteroidalantiinflammatorydrugsandsusceptibilitytocovid19 AT wangjingya nonsteroidalantiinflammatorydrugsandsusceptibilitytocovid19 AT adderleynicolaj nonsteroidalantiinflammatorydrugsandsusceptibilitytocovid19 AT tavernerthomas nonsteroidalantiinflammatorydrugsandsusceptibilitytocovid19 AT dennistonalastairk nonsteroidalantiinflammatorydrugsandsusceptibilitytocovid19 AT lordjanet nonsteroidalantiinflammatorydrugsandsusceptibilitytocovid19 AT thomasgneil nonsteroidalantiinflammatorydrugsandsusceptibilitytocovid19 AT buckleychristopherd nonsteroidalantiinflammatorydrugsandsusceptibilitytocovid19 AT razakarim nonsteroidalantiinflammatorydrugsandsusceptibilitytocovid19 AT bhalaneeraj nonsteroidalantiinflammatorydrugsandsusceptibilitytocovid19 AT nirantharakumarkrishnarajah nonsteroidalantiinflammatorydrugsandsusceptibilitytocovid19 AT haroonshamil nonsteroidalantiinflammatorydrugsandsusceptibilitytocovid19 |